Pfizer’s Ibrance® in Combination With Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 Patina Study in Patients With Hr+, Her2+ Metastatic Breast Cancer
輝瑞的Ibrance®與標準治療聯合使用在HR+、HER2+轉移性乳腺癌患者的III期Patina研究中將中位無進展生存期延長超過15個月。
